PTC Therapeutics reported record quarterly total revenue of $361 million for the second quarter of 2026, driven by strong product sales and royalty income, and raised its full-year 2026 product revenue guidance to between $850 million and $950 million. Product revenue reached $239 million, more than doubling from $118 million in the same quarter last year, while total revenue guidance for the year was increased to a range of $1.18 billion to $1.28 billion. The company's phenylketonuria drug Sephience generated $151 million in global net product revenue, a 21 percent increase from the previous quarter, with 1,647 commercial patients on therapy worldwide as of June 30, 2026. The Duchenne muscular dystrophy franchise contributed $67 million, Translarna net product revenue was $42 million including a Russian government purchase order, Emflaza net product revenue was $25 million, and Evrysdi royalty revenue was $71 million based on Roche's global revenue of approximately $628 million. PTC Therapeutics ended the quarter with $2.23 billion in cash, equivalents, and marketable securities, and management expressed confidence in the potential for cash flow breakeven during 2026.
PTC Therapeutics IncRecord revenue and raised guidance
Roche Holding AGEvrysdi royalty revenue based on Roche's global sales
Commercial Metals Company